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Abstract
Introduction: The aim of this study was to explore the presence and localization of myocardial citrullination in
samples from rheumatoid arthritis (RA) patients compared to rheumatic and non-rheumatic disease control groups.
Methods: Archived myocardial samples obtained during autopsy from 1995 to 2009 were assembled into four
groups: RA; scleroderma; fatal myocarditis; and non-rheumatic disease controls. Samples were examined by
immunohistochemistry (IHC) for the presence and localization of citrullination and peptidyl arginine deiminase
enzymes (PADs) by a single cardiovascular pathologist blinded to disease group and clinical characteristics.
Results: Myocardial samples from seventeen RA patients were compared with those from fourteen controls, five
fatal myocarditis patients, and ten scleroderma patients. Strong citrullination staining was detected exclusively in
the myocardial interstitium in each of the groups. However, average and peak anti-citrulline staining was 59% and
44% higher, respectively, for the RA group compared to the combined non-RA groups (P < 0.05 for both
comparisons). Myocardial fibrosis did not differ between the groups. In contrast to citrullination, PADs 1 to 3 and 6
were detected in cardiomyocytes (primarily PADs 1 and 3), resident inflammatory cells (primarily PADs 2 and 4),
and, to a smaller extent, in endothelial cells and vascular smooth muscle cells. PAD staining did not co-localize
with anti-citrulline staining in the interstitium and did not vary by disease state.
Conclusions: Staining for citrullination was higher in the myocardial interstitium of RA compared to other disease
states, a finding that could link autoimmunity to the known increase in myocardial dysfunction and heart failure in
RA.
Background
Rates of heart failure and diastolic dysfunction are
increased in rheumatoid arthritis (RA) patients com-
pared to non-RA controls independent of coronary
artery disease [1], suggesting that myocardial remodeling
occurs as part of the RA disease process. The phenotype
of heart failure in RA differs from that of non-RA
patients, characterized by fewer symptoms, lower blood
pressure, and higher ejection fraction at presentation
[2], suggesting that the pathophysiologic mechanisms
underlying the progression to heart failure in RA may
differ from the general population. Reports of increased
myocarditis and vasculitis in autopsied RA hearts com-
pared to controls date back more than five decades
[3,4]. However, the myocardium as a potential autoim-
mune target in rheumatoid arthritis has received little
direct investigation since that time.
Recently, we reported an association of a higher con-
centration of serum anti-cyclic citrullinated peptide
(anti-CCP) antibodies with lower myocardial mass and
smaller left ventricular chamber volumes in RA patients
without known cardiovascular disease [5]; raising the
possibility that RA-specific autoimmunity against citrul-
linated proteins might mediate changes to myocardial
morphology that, in turn, may affect myocardial func-
tion. Citrullination, the post-translational modification
of arginine to citrulline catalyzed by a set of peptidyl-
arginine deiminase enzymes (PADs), is abundant in the
rheumatoid synovium but not restricted to RA [6].
Citrullinated proteins have been identified in the
affected tissues of a number of inflammatory conditions,
such as muscle in myositis patients, myelin sheaths in
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multiple sclerosis, and intestinal mucosa in inflamma-
tory bowel disease [7] and in non-pathologic tissues
with homeostatic functions, such as keratinized
epithelium.
What are the potential links between circulating anti-
citrullinated peptide antibodies (ACPA) and the myocar-
dium? Many of the protein targets that undergo citrulli-
nation in rheumatoid synovium (that is, vimentin,
enolase, fibronectin) and are targets for ACPA in RA [8]
are also present in the myocardium [9]. However, it is
unknown whether citrullination of myocardial proteins
is present in RA. For this investigation, we explored the
presence, abundance, and localization of citrullination in
archived myocardial samples from RA patients com-
pared to a variety of rheumatic and non-rheumatic dis-
ease control groups. Further, we explored co-localization
of citrullination with histologic features and the pre-
sence of human PAD isotypes. We hypothesized that
myocardial citrullination would be unique to, or more
abundant in, RA compared to other conditions, and that
myocardial regions demonstrating citrullination would
co-localize with evidence of tissue damage (for example,




The study was approved by the Institutional Review
Board of The Johns Hopkins Hospital, which waived the
need for obtaining decedent informed consent for use of
archived myocardial samples and records. Myocardial
samples acquired at autopsy from individuals with RA
were identified using a series of ascertainment and adju-
dication steps. First, an initial search was conducted of
the Johns Hopkins Anatomic Pathology database for
mention of the term ‘rheumatoid arthritis’ within the
text of any autopsy report performed between January 1,
1995 and July 1, 2009. The start date was chosen as RA
diagnosis and treatment practices would be more con-
sistent with current practices, and preservation and
organization of samples would be superior to those
stored prior. Also, case adjudication was facilitated using
the Electronic Patient Record system of The Johns Hop-
kins Hospital, with records available from 1995 onward.
We created a standard data abstraction tool for each
disease group and determined, a priori, the extractable
data elements that would constitute definite, possible,
and unlikely for each condition. Categorization as RA
required at least two outpatient clinic evaluations by a
rheumatologist in which RA was identified as the diag-
nosis with indication of active small joint polyarthritis
or clinical joint deformities typical for RA plus treat-
ment with medications typically used for the treatment
of RA (that is, biologic and non-biologic disease
modifying anti-rheumatic drugs [DMARDS]). Possible
and unlikely cases had more limited clinical information
available. Data were abstracted by a single study team
member (JP and adjudicated by agreement between two
study rheumatologists (JTG and JMB). Of the 49 poten-
tial cases with ‘RA’ mentioned in the autopsy report, 20
adjudicated RA cases, five possible, and 24 unlikely
cases were identified. Of the RA cases, 17 had available
myocardial samples and constituted the RA group used
for histopathology.
Control sample identification
Controls without rheumatic disease or myocarditis were
selected in a similar manner as described for the RA
cases and group matched on age to the RA group. For
the scleroderma group, an initial Pathology database
query identified 28 potential cases with specimens since
1995. Of these, further review with the scleroderma data
abstraction tool yielded 14 adjudicated definite, three
possible, and 11 unlikely cases. Among the definite
cases, 10 had available myocardial samples. For myocar-
ditis, only lymphocytic and eosinophilic myocarditis
cases were included. Of the 56 potential cases identified
from the initial Pathology database query, 14 met inclu-
sion criteria for the desired myocarditis characteristics;
however, only five had myocardial specimens available
for histopathology.
Clinical characteristics
Gender and ethnicity were collected from medical
records. Age at death, postmortem interval ([PMI], the
time in hours between death and autopsy), and the pre-
sence and severity of coronary atherosclerosis were col-
lected from autopsy records. Other characteristics,
including cardiac history, were not uniformly available
or reliable among all individuals with samples, and were
thus not used for analysis beyond confirmation of
diagnosis.
Histopathology and immunohistochemistry
Autopsy blocks, of the left ventricular free wall, were
obtained from the archives of the Johns Hopkins
Department of Pathology. Five-micron sections were cut
and placed on charged slides. These were immersed in
Trilogy rinse (Cell Marque, Hot Spring, AR, USA) and
placed in an electric pressure cooker until reaching 127°
C and 17 psi. Slides stained for citrulline were modified
in a strong acid solution containing 2.3-butanedoine for
3 h at 37°C. Endogenous peroxidase activity was blocked
by incubation in 0.3% H2O2 in methanol for 18 min.
Non-specific protein activity was blocked by incubation
with a non-serum protein solution (DAKO Corporation,
Carpinteria, CA, USA). Slides were incubated with anti-
bodies targeting PAD1 (1:1000 Abcam, Cambridge, MA,
USA), PAD2 (1:200, Abcam), PAD3 (1:500, Abcam,
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PAD4 (1:150, Sigma-Aldrich, St Louis, MO, USA),
PAD6 (1:150 Abcam) or citrulline (1:1000, Millipore
Corporation, Billerica, MA) overnight at 4°C. For anti-
PAD1, slides underwent an additional treatment with
HRP polymer detection kit (Invitrogen, Carlsbad, CA,
USA). Sections were then incubated with biotinylated
donkey anti-rabbit IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA).
Immunoperoxidase staining was performed using Vec-
tastain ABC Elite (Vector Labs, Burlingame, CA, USA).
The avidin-biotin complex was visualized using 3.3’ dia-
minobenzidine (DAB) peroxidase substrate (Vector
Labs). Sections were counterstained in hematoxylin
(Richard-Allen, Kalamazoo, MI, USA).
All cardiac tissue scoring of the myocardium was
performed by a single-blinded cardiovascular patholo-
gist (MKH). Citrullination staining was based on a 5-
point scale (1 to 3 in 0.5 increments) corresponding to
minimal, moderate, and marked citrullination staining.
Both an overall staining score and a peak staining
score were generated for each tissue as there was some
heterogeneity in staining intensity across the slides.
Cardiac hypertrophy was measured subjectively based
upon the surrogate nuclear features of size, hyperchro-
masia, and irregularity of the nuclear membranes [10].
Myocarditis was initially reported in the autopsy
record and was confirmed through the histopathologic
findings of lymphocytic infiltration causing myocyte
injury. Areas of fibrosis included both interstitial
(fibrosis between myocytes) and replacement (fibrotic
bands replacing myocytes) types and were scored using
the same semi-quantitative scale. Scoring of PAD
staining was also performed blinded using the same 1
to 3 scale. Staining was independently evaluated and
scored for the myocytes, smooth muscle cells, endothe-
lium, and leukocytes.
Statistical analysis
The distributions of clinical and histologic characteris-
tics were examined and compared between groups using
analysis of variance (ANOVA), with Bonferonni correc-
tion, for normally distributed continuous variables, the
Kruskal-Wallis test for non-normally distributed contin-
uous variables, and the chi-square goodness of fit test or
Fisher’s exact test, as appropriate, for categorical vari-
ables. Generalized linear models were constructed to
explore the associations of patient characteristics with
average and peak citrullination scores in the RA and
control groups, with heterogeneity in the associations
between groups tested using analysis of co-variance
(ANCOVA). The Shapiro-Wilk test was used to ensure
normality of the modeled outcome variables across the
extent of independent variables. All calculations were
performed using Intercooled Stata 10 (StataCorp,
College Station, TX, USA). In all tests, a two-tailed a of
0.05 was utilized.
Results
Characteristics of the disease groups are summarized in
Table 1. Compared to the control group, the RA group
did not differ in magnitude or significance by age at
autopsy, gender, ethnicity, PMI, or the presence/extent
of reported coronary atherosclerosis. In addition, there
were no differences between the RA and control groups
in histologic evidence of myocarditis, myocardial inter-
stitial fibrosis, replacement fibrosis, or cardiomyocyte
hypertrophy. For the myocarditis and scleroderma
groups, there were differences in demographics com-
pared with the RA and control groups. Specifically, the
scleroderma group was significantly younger at death,
on average, than either the RA or control groups. The
proportion of Caucasians was lower in the scleroderma
group compared to the RA or control groups, although
these differences did not reach statistical significance.
Gender was similar among the groups, except for the
myocarditis group, in which the proportion of women
was lower than either the RA or control groups (P =
0.028 and 0.26, respectively). PMI did not differ signifi-
cantly for either the myocarditis or scleroderma groups
compared to the RA or control groups.
Quantification and localization of myocardial citrullination
Histologic staining for citrullination was localized exclu-
sively in the perivascular interstitium of RA (Figure 1a),
control (Figure 1b), myocarditis, and scleroderma sam-
ples. At an antibody concentration of 1:1000, citrullina-
tion was not identified in the cardiomyocytes,
endothelium, vascular smooth muscle cells (VSMCs), or
infiltrating myocardial inflammatory cells. The mean
average (Figure 2a) and peak (Figure 2b) citrullination
scores were similar between the control, myocarditis,
and scleroderma groups. Compared to these groups, the
mean average and peak myocardial anti-citrulline stain-
ing intensity scores were 59% and 44% higher, respec-
tively, for the RA group compared to the combined
non-RA groups (P < 0.001 for both differences). These
differences remained significant even after adjusting for
age, gender, and ethnicity. In contrast, mean average
scores for staining for myocardial fibrosis were similar
between all groups (Figure 2c). Areas of high intensity
citrullination staining did not co-localize with areas of
inflammation seen in myocarditis.
Associations of myocardial citrullination with patient
characteristics
We explored the associations of the uniformly available
demographic and histologic characteristics (that is, age,
gender, ethnicity, PMI, and histologic evidence of
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myocarditis, interstitial and replacement fibrosis, and
cardiomyocyte hypertrophy) with mean average and
peak citrullination scores. Higher age was associated
with higher mean average citrullination in both the RA
and control groups (Figure 3a); however, the magnitude
of the association of age with average citrullination was
greater in the RA vs. control group, and was only statis-
tically significant in the RA group. Gender, ethnicity,
PMI, and presence/extent of reported coronary athero-
sclerosis were not associated with the extent of citrulli-
nation in either the RA or control groups (data not
shown). Among histologic findings, the mean average
citrullination score was almost 1 unit higher among RA
patients with evidence of interstitial fibrosis compared
to those without fibrosis (Figure 3b; P = 0.005). In con-
trast, an association of interstitial fibrosis with citrullina-
tion was not observed among controls. The magnitude,
direction, and significance of the associations of age and
interstitial fibrosis with average citrullination score were
not substantially changed when age and interstitial
fibrosis were co-modeled. Cardiomyocyte hypertrophy
was not associated with citrullination in either group.
There was no significant association of myocarditis with
citrullination in the control group and, since no RA
patients had evidence of myocarditis, no association
could be explored in this group. Associations of patient
characteristics with mean peak citrullination scores were
similar to those observed with average citrullination in
magnitude and direction among both groups (data not
shown).
Quantification and localization of myocardial PADs
Semi-quantitative assessments and localization of PADs
from myocardial samples are summarized in Table 2.
There were no meaningful differences in PAD staining
intensity in any cellular compartment between RA and
Table 1 Demographic and histologic characteristics according to study group
RA (n = 17) Control (n = 14) Myocarditis (n = 5) Scleroderma (n = 10) Pa
Demographics and reported autopsy features
Age, years 68 ± 12 67 ± 12 61 ± 13 54 ± 13 0.85
Female, n (%) 15 (88) 11 (79) 2 (40) 7 (70) 0.64
Caucasian, n (%) 12 (71) 12 (86) 4 (80) 5 (50) 0.41
PMI, median (%) 19 (13-23) 20 (9-28) 25 (21-27) 24 (19-39) 0.92
Coronary atherosclerosis, any reported; n (%) 7 (41) 7 (50) 2 (40) 4 (40) 0.62
Mild or moderate, n (%) 4 (24) 6 (43) 1 (20) 3 (30) 0.44
Severe, n (%) 3 (18) 1 (7) 1 (20) 1 (10) 0.60
Histologic findings
Myocarditis, n (%) 0 (0) 1 (6) 5 (100) 0 (0) 1.00
Interstitial fibrosis, n (%) 14 (81) 12 (86) 3 (60) 7 (70) 1.00
Replacement fibrosis, n (%) 3 (19) 4 (29) 1 (20) 3 (30) 0.68
Cardiomyocyte hypertrophy, n (%) 11 (63) 9 (64) 2 (40) 7 (70) 1.00
aP value for RA vs. control groups.
PMI, postmortem interval; RA, rheumatoid arthritis.
Figure 1 Representative sections are shown demonstrating anti-citrulline staining in rheumatoid arthritis myocardium (A) and control
myocardium (B). Citrullination was restricted to the myocardial interstitium in both groups, with staining intensity qualitatively higher in the RA
group. Interstitial citrullination was also observed in myocardial samples from fatal myocarditis and scleroderma patients with a qualitative
intensity similar to the control group (not depicted).
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control samples. In contrast to citrullination, PADs were
not detected in the extracellular matrix of the myocar-
dial interstitium and localization of PAD isotypes to spe-
cific regions of the myocardium was noted. PAD1
strongly stained perinuclear cytoplasmic granules of car-
diomyocytes (Figure 4, top left) and, to a much lesser
extent, leukocytes. PAD2 was observed primarily in leu-
kocytes (Figure 4, top middle) and at very low back-
ground levels among the other myocardial cell types.
Strong PAD3 staining was observed in cardiomyocytes
(Figure 4, top right), which, in contrast to the cytoplas-
mic granules staining for PAD1, primarily stained in the
region of the nucleus. Weaker PAD3 staining was
observed in vascular smooth muscle cells (VSMCs) and
in leukocytes. Strong PAD4 staining was observed in
leukocytes (Figure 4, bottom left) and weak staining was
observed in other cell types. PAD6 was observed in low
background levels diffusely in the cytoplasm of cardio-
myocytes (Figure 4, bottom middle), but moderately
stained VSMCs and endothelium (Figure 4, bottom
right).
Discussion
To the best of our knowledge, this is the first report of
the presence of myocardial citrullination in any disease
state, and the first histologic description of staining
Figure 2 Mean average (A) and peak (B) citrullination scores, and mean average fibrosis score (C) according to disease group. Mean
and 95% confidence intervals are depicted.
Figure 3 Associations of age (A) and myocardial fibrosis (B) with average citrullination, according to RA status. For age, the average
linear association is depicted (least-squares estimate) for the RA (b = 0.044; P < 0.05) and control (b = 0.032; P < 0.05), a difference in slopes that
was significant (P value for interaction = 0.040). Dashed lines in panel A indicate 95% confidence intervals. For panel B, bars indicate means with
fences representing the standard error of the mean.
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patterns of all known human PAD isotypes in myocar-
dial tissues. These data provide evidence that: (1) citrul-
linated proteins are present in the myocardial
interstitium of diverse disease states, but significantly
increased in RA; (2) demographics, postmortem interval,
and the presence or extent of reported coronary athero-
sclerosis did not account for higher citrullination in RA;
and (3) a variety of PADs are present in the myocar-
dium, but they do not co-localize with interstitial citrul-
lination. Our finding that citrullination was indeed
present in the myocardium extends the list of tissues
known to undergo this form of post-translational modi-
fication. Although we did not identify specific citrulli-
nated proteins in this investigation, the localization of
citrullination to the interstitium may provide clues as to
likely candidates. Proteins found in the interstitium are
primarily those of extracellular matrix (ECM) and pro-
teins that interact with ECM (for example, collagens,
fibronectin, laminin) [11]; however, while these are the
most common interstitial proteins, the list of additional
candidate proteins remains extensive. Our finding that
age was more strongly associated with citrullination in
RA compared to controls could suggest that citrullina-
tion is an expected aging-related phenomenon acceler-
ated in RA by processes that remain to be elucidated,
perhaps related to accelerated apoptosis or autophagic
death of cardiomyocytes or cardiac leukocytes. Neither
myocarditis nor myocyte necrosis were frequent among
RA samples, suggesting that fulminant processes such as
these may not be the triggers for citrullination. More-
over, the lack of citrullination above control levels
among fatal myocarditis patients further supports a lack
of association. Another interesting finding was higher
citrullination scores among RA samples with evidence
of interstitial fibrosis. The association suggests that the
two processes may be linked; however, whether
Table 2 Summary of the presence, extent, and localization of citrullination and PAD isotypes in the myocardium of RA
patients
Cardiomycocytes VSMCs Endothelium Leukocytes Extracellular matrix
Citrullination Absent Absent Absent Absent +++
PAD1 +++a Absent Absent + Absent
PAD2 +b + + +++ Absent
PAD3 +++a, c ++ + ++ Absent
PAD4 +b + + +++ Absent
PAD6 +b ++ ++ Absent Absent
aGranular staining pattern; bcytoplasmic staining pattern; cnuclear staining pattern.
PAD, peptidyl-arginine deiminase; VSMC, vascular smooth muscle cells.
Figure 4 Representative images of PAD staining of the cardiac myocytes. The second PAD6 image demonstrates vascular smooth muscle
cell and endothelial cell staining (original magnifications 100×).
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interstitial fibrosis and citrullination are causally linked,
or merely epiphenomena, is not evident from our study.
There is precedent for other mechanisms of post-
translational modification of myocardial proteins leading
to changes in cardiac structure and function. Phosphor-
ylation, oxidation, and glycation of sarcomeric proteins
cause morphologic changes to proteins that lead to
increased protein cross-linking, resulting in increased
ventricular stiffness [12]. Beyond direct structural effects
related to altered protein-protein interaction, accumula-
tion of modified proteins has been shown to mediate
myocardial fibrosis via modulation of the expression of
proteases and transcription factors in myocardial fibro-
blasts [13]. It is unknown whether citrullination of myo-
cardial proteins leads to altered interaction of
myocardial proteins or cellular processes leading to
interstitial fibrosis similar to other post-translational
modifications; however, our findings warrant additional
study into possible mechanisms.
Although citrullination appears to be a generalized
process, autoantibodies targeting citrullinated proteins
are relatively specific for RA and, although occasionally
observed in other autoimmune conditions, are uncom-
monly observed in healthy individuals [14]. Thus, RA
patients may be uniquely at risk for autoreactivity
against proteins that, upon citrullination, function as
neo-epitopes for anti-citrulline autoantibodies. RA
patients are known to exhibit a broader repertoire of
reactivity against citrullinated peptides compared to
non-RA patients with ACPA antibodies [8], a process
potentiated by epitope spreading [15]. Although it is not
known from our study whether myocardial citrullinated
proteins are immune targets for circulating autoantibo-
dies, or whether autoimmunity against citrullinated pro-
teins mediates phenotypic modifications to cardiac
structure or function, this is a goal of ongoing
investigation.
The cellular localization of PAD isotypes within the
myocardium has not been previously described. While
PADs 1 and 3 are primarily regarded as epidermal in
origin, mRNA for PAD1 has been identified in muscle
tissue [16]. In addition, our finding of PADs 2 and 4 pri-
marily in leukocytes is expected from previous investiga-
tion [17]. Somewhat unexpected was the observation of
a clear separation between the locations of citrullination
and PADs in the myocardium in all of the disease
groups, a finding that warrants further study.
Some notable study limitations deserve acknowledg-
ment. Most notably, samples derived from autopsy may
not represent processes active in life, findings may be
influenced by cause of death, samples tend to be derived
from older individuals and thus may misrepresent nat-
ural history over the course of disease, and histopathol-
ogy may be affected by the interval between death and
sample collection (that is, PMI). Because of slow pro-
gression and infrequency of fulminant symptoms, the
diagnosis and management of myocardial dysfunction in
RA patients rarely requires endomyocardial biopsy, lim-
iting the spectrum of myocardial samples available. Even
so, samples collected for clinical diagnostics could be
biased by the factors necessitating biopsy (that is, skew-
ing toward patients with extreme findings). Regarding
the potential for PMI to confound our findings, we did
not observe an influence of PMI on anti-citrulline detec-
tion, suggesting that citrullination is stable post mortem.
Another limitation was the lack of clinical data, particu-
larly for RA features and treatments. While richer clini-
cal data would be helpful in exploring factors linked to
citrullination within the RA group, notably the presence
or absence of ACPA, the absence of the clinical charac-
teristics does not impugn the differences detected com-
paring RA vs. non-RA disease states. As with any IHC-
based study, antibody titer can affect where staining is
observed. We used a low titer for our anti-modified
citrulline antibody and saw robust staining in the extra-
cellular matrix. A 10-fold higher titer of antibody did
show myocardial staining, but it was difficult to discern
this from background staining indicating that myocyte
citrullination needs to be confirmed by a separate
method. Finally, a strength of the investigation was the
development a priori of standardized data abstraction
tools and criteria for each disease group, with samples
analyzed only for cases identified as definite or highly
probable.
Conclusions
In summary, our novel detection of citrullinated pro-
teins within the interstitium of the myocardium may
have implications for cardiac physiology, both for RA
patients and the general population. More extensive
citrullination linked to the RA disease state, and the
more robust association of age and interstitial fibrosis
observed in RA compared to non-RA groups, may con-
tribute to higher rates of myocardial dysfunction and
overt heart failure in RA that deserves additional
investigation.
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